Amel Tounsi

Noshaq SA is an independent private equity/venture capital firm founded in 1985. Noshaq SA is headquartered in Liege.

ANALIS manufactures and distributes instruments and furniture for laboratories. The private company is based in Namur, Belgium. and has subsidiaries in France. The Belgian company was founded in 1927. Vincent Luyckx has been the CEO of the company since 2016.

Bridge2Health SA provides biomedical translational research services. It offers services to the clinicians, basic researchers and pharmaceutical industries. The firm also provides blueprint for biobank query and retrieval between universities. The company was founded in September 2012 and is headquartered in Liege, Belgium.

MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium.

Cerhum SA engages in the manufacture of dental equipment and supplies. Its products include MyBone and technical ceramics. It offers bone graft and dental printing, ceramic and plastic prototyping, small series production, three dimensional scanning services. The company was founded by Grégory Nolens and Caroline Remacle in 2015 and is headquartered in Liege, Belgium.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.